Cart
sales@molnova.com
Enoximone
CAS No. 77671-31-9
Enoximone( —— )
Catalog No. M21990 CAS No. 77671-31-9
Enoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 82 | In Stock |
|
| 10MG | 120 | In Stock |
|
| 25MG | 237 | In Stock |
|
| 50MG | 426 | In Stock |
|
| 100MG | 624 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEnoximone
-
NoteResearch use only, not for human use.
-
Brief DescriptionEnoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.
-
DescriptionEnoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.Perioperative Enoximone administration improved renal function in patients undergoing on-pump cardiac surgery.(In Vitro):In vitro, 10 μM Enoximone-treated bronchoalveolar lavage (BAL) eosinophils induced by IL-33 treatment shows significantly lower CD11b expression when compared with diluent-treated BAL eosinophils.(In Vivo):Topical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM)-induced allergic airway inflammation.The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation.
-
In VitroIn vitro, 10 μM Enoximone-treated bronchoalveolar lavage (BAL) eosinophils induced by IL-33 treatment shows significantly lower CD11b expression when compared with diluent-treated BAL eosinophils.
-
In VivoTopical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM)-induced allergic airway inflammation.The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE3
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number77671-31-9
-
Formula Weight248.3
-
Molecular FormulaC12H12N2O2S
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 8.33 mg/mL (33.55 mM)
-
SMILESCSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Emiliano Angeloni , Giovanni Melina , Francesco Federici,et al.Preliminary Results of the Multicenter Observational Study With Enoximone in Cardiac Surgery (MOSEC).Observational Study Int J Cardiol. 2018 Oct 15;269:51-55.
molnova catalog
related products
-
ATX inhibitor 5
ATX inhibitor 5 is a potent and orally active autotaxin (ATX) inhibitor (IC50: 15.3 nM) that reduces CCl4-induced hepatic fibrosis and exhibits anti-hepatic fibrosis effects.
-
HA155
HA155 selectively and potently inhibits autotaxin with an IC50 of 5.7 nM.
-
MBCQ
MBCQ is an inhibitor of cGMP-specific phosphodiesterase PDE5.MBCQ, a selective PDE5 inhibitor, significantly decreased the EC(50) values for GTN-induced relaxation in both tolerant and nontolerant tissues, but with the greatest relative shift occurring in tolerant veins.
